leadf
logo-loader
viewTetra Bio-Pharma

Tetra Bio reveals CBD inhalation is safer than oral administration by studying its QIXLEEF drug

Tetra Bio-Pharma Inc (TSX:TBD) (OTCQB:TBPMF) CEO Guy Chamberland tells Proactive the group has mapped out CBD metabolites in humans who were administered QIXLEEF by vaporization.

Chamberland says defining QIXLEEF, used to treat pain in cancer patients, is a critical step for the FDA and Health Canada to characterize the safety profile of the drug product in patients consuming cannabis.

Quick facts: Tetra Bio-Pharma

Price: - -

TSX-V:TBP
Market: TSX-V
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Tetra Bio-Pharma acquires Canadian rights to Dronabinol Soft Gel capsules,...

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) Chief Commercial Officer Steeve Néron tells Proactive the biotech has acquired the Canadian exclusive rights for Dronabinol Soft Gel capsules, cannabinoid derived prescription drug aimed to treat AIDS-related anorexia and severe nausea and vomiting...

3 weeks, 1 day ago

2 min read